LRRK2 and Parkinson disease: Longer-term monitoring will be critical to assess safety of chronic dosing with LRRK2 kinase inhibitors on lung and kidney function, as well as in PD patients with clinically significant history of pulmonary and kidney disease, which are often co-morbidities in this population.